Recent changes
GovPing monitors 142 sources for this role across Guidance, Enforcement, Rule, Notice, and Consultation, out of 2,503 total sources on the platform. The past week saw 602 changes across these sources.
FDA issued a Warning Letter to Purolea Cosmetics Lab for CGMP violations, while also warning Dry Springs Pharmacy for unlawful opioid sales. A Class I recall of Philips Trilogy Evo ventilators highlights a serious device safety issue. The Class I recall of Draeger Atlan A350 anesthesia workstations further underscores critical equipment risks.
CLDN18.2 binding molecule patent granted to Sanyou
CLDN18.2 binding molecule patent granted to Sanyou
Monoclonal antibody matrix metalloproteinase-1 patent granted
USPTO granted Patent US12595315B2 to S&T BIOMED CO., LTD. for a monoclonal antibody specific to matrix metalloproteinase-1. The patent covers the antibody's heavy and light chain variable regions with specific CDR sequences, along with polynucleotides, detection kits, and detection methods. This grant date is April 7, 2026.
TfR1 Humanized Antibodies and Cancer Treatment Methods
The USPTO issued Patent US12595310B2 to The Regents of the University of California covering transferrin receptor 1 (TfR1)-binding proteins, including humanized antibodies and methods for treating cancer. The patent, granted on April 7, 2026, includes 20 claims and was filed on November 6, 2020 under Application No. 17775167. The invention relates to humanized TfR1-binding proteins with amino acid substitutions, combination treatments with additional therapeutics, and methods for cancer therapy.
GPC3 antibody patent - methods of use for cancer treatment
The USPTO granted patent US12595314B2 to R.P. Scherer Technologies, LLC for antibodies specific to glypican-3 (GPC3). The patent covers 37 claims including the antibody compositions, nucleic acids encoding the antibodies, methods of manufacturing, and therapeutic uses for treating cell proliferative disorders by enhancing immune responses such as T cell responses to cancer cells.
6-Thio-dG Treatment for Pediatric Brain Tumors
The USPTO granted Patent US12594293B2 to The Board of Regents of The University of Texas System on April 7, 2026, covering the use of 6-thio-dG (a telomerase substrate precursor analog) to treat therapy-resistant telomerase-positive pediatric brain tumors including diffuse intrinsic pontine glioma (DIPG), high-grade glioma (HGG), and high-risk medulloblastoma. Inventors Jerry Shay and Rachid Drissi developed methods demonstrating that 6-thio-dG induces telomere dysfunction-induced foci, genomic DNA damage, cell death, and tumor growth delay in xenograft models.
CDC Drug Overdose Data Collection - Comment Request
The CDC has issued a consultation document requesting public comments on drug overdose data collection methods and reporting requirements. The document seeks input on proposed data collection standards that state and local health departments would use to report overdose surveillance data to the CDC. Comments are due by June 8th.
CDC NNDSS Surveillance Update, Comment Deadline June 8
The CDC published a surveillance update to the National Notifiable Diseases Surveillance System (NNDSS), with public comments requested by June 8. The NNDSS is a nationwide system for tracking notifiable diseases reported by state and territorial health departments. Healthcare providers, laboratories, and public health authorities submitting disease data to CDC should review the proposed changes and submit feedback.
Quorum Sensing Compositions and Methods for Microbial Community Modulation
USPTO granted patent US12594307B2 to The Regents of the University of California for quorum sensing compositions and methods for modulating bacterial quorum sensing. The patent covers engineered bacterial strains with multiple activator polypeptide-encoding sequences and methods for tunable dynamics in microbial communities. Inventors include Jeff Hasty, Arianna Miano, and Michael Julius Liao, with applications spanning synthetic biology and therapeutic development.
Virus-like Particles Patent Granted to University of Denver
The USPTO granted Patent US12594329B2 to the University of Denver on April 7, 2026. The patent covers virus-like particles, compositions, antibody detection tests using virus-like particles, and methods of producing non-replicating virus-like particles from modified viral genomes. Schuyler B. van Engelenburg is the sole inventor of the 9-claim patent.
Temperature-Optimized Bacillus Strains Patent Grant
The USPTO granted patent US12593849B2 to Chr. Hansen A/S on April 7, 2026, covering new strains of Bacillus paralicheniformis with improved growth rates and plant growth promoting properties. The patent names six inventors including Patricia Dominguez Cuevas and Lars Moelbak, with 21 claims. Filing date was August 28, 2020, under application number 17638152.
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
602 changes in last 7 days
Latest high priority updates
142 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.